MeCure Healthcare Limited has unveiled its first ever cyclotron and PET-CT scan, a device that produces tracers and other radiopharmaceutical reagents which can be used to detect the physiological activities of cancer cells in the body.
The acting Director General of National Agency for Food and Drug Administration and Control , Dr. Monica Eimunjeze, who unveiled the project, said it will ensure targeted interventions, early detection and better management of patients who have cancer, adding that the costs are cheaper in the country than buying a ticket to travel abroad for the treatment.
She expressed delight about the partnership with Mecure, saying that respite will come to patients who have the disease in Nigeria.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: